AIT-082 Phase 1B Study

National Institutes of Health (NIH) logo

National Institutes of Health (NIH)

Status and phase

Completed
Phase 1

Conditions

Memory Disorders

Treatments

Drug: AIT-082

Study type

Interventional

Funder types

NIH

Identifiers

NCT00000180
IA0008
3U01AG010483-08S2 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits. This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems